Orion Biotechnology Canada

Orion Biotechnology Canada, Ltd.Founded in 2017 and headquartered in Ottawa, Canada, Orion Biotechnology Canada, Ltd. focuses on the research and development of therapeutics aimed at metabolic disorders.Orion Biotechnology is focused on the research and development of innovative therapeutics targeting metabolic G Protein-Coupled Receptors (GPCRs), particularly for obesity and metabolic disorders. The company's primary product candidates include OB-002, an injectable peptide, and OB-003, an oral small molecule, both aimed at modulating the GPR75 receptor, a novel target for obesity treatment. These candidates have shown consistent efficacy in preclinical evaluations and are poised to enter clinical development. Orion’s proprietary PROcisionX™ platform streamlines the drug discovery process, enabling the rapid development of therapeutics from target identification to optimized lead within six months.Orion Biotechnology's revenue model is primarily structured around partnerships and collaborations within the pharmaceutical industry, specifically focusing on out-licensing opportunities and R&D collaborations related to its PROcisionX™ platform. Typical transactions may involve licensing agreements where clients gain access to Orion's proprietary technology for the development of their own GPCR-targeting therapeutics. These agreements may also encompass milestone payments based on the progress of clinical trials and sales royalties upon successful commercialization of products.5 mn in June 2021, Orion Biotechnology Canada, Ltd. The company aims to extend its proprietary discovery platform and is focused on expanding its presence in North America and Europe, targeting the launch of new products within the next two years.

1. Series A

   Mar 24, 2021

   Amount

   Undisclosed

   Investors

   Locked